NSCLCs with Bcl-2-interacting mediator of cell death (BIM) deletion polymorphisms are primarily resistant to osimertinib.7 TKI resistance is a leading cause of recurrence, progression, treatment failure, low compliance and mortality among cancer patients. This evidence concerns the gene BCL2L11 and cancer.